Variant bacterial strains and processes for protein or biomass production
AssigneeSolar Foods Oy
InventorsTytti JÄMSÄ, Juha-Pekka PITKÄNEN, Laura SALUSJÄRVI
Life of this patent
Estimating the term…
Loading patent…
AssigneeSolar Foods Oy
InventorsTytti JÄMSÄ, Juha-Pekka PITKÄNEN, Laura SALUSJÄRVI
Estimating the term…
Variant chemoautotrophic bacteria of the genus Xanthobacter including a genetic modification that reduces the bacterial production of polyhydroxyalkanoic acids. Furthermore, the present disclosure relates to continuous culture processes for the production of protein or biomass using variant chemoautotrophic bacteria, said process including supply of gases and minerals to the cells. The present disclosure also relates to the products of these processes and use of these products in e.g. food or feed. Reference is made to the Identification of the Microorganism, having the Identification reference given by the DEPOSITOR of SoF1-2.0 and with the Accession number given by the INTERNATIONAL DEPOSITORY AUTHORITY of VTT E-213595. The date of the original deposit is Apr. 19, 2021
A variant of bacterial strain VTT-E-193585 comprising a genetic modification that reduces the bacterial production of polyhydroxyalkanoic acid (PHA) as compared to strain VTT-E-193585.
A variant Xanthobacter strain comprising a gene disruption of one or more genes encoding a PHA synthase.
A process for the production of biomass, said process comprising culturing a variant chemoautotrophic bacterial strain in continuous culture with hydrogen as energy source and an inorganic carbon source, wherein the inorganic carbon source comprises carbon dioxide and wherein said variant chemoautotrophic strain comprises a gene disruption of one or more genes encoding a PHA synthase.
A method for genetic modification of bacterial strain VTT-E-193585 comprising the steps of:
A variant of bacterial strain VTT-E-193585 comprising a genetic modification wherein said genetic modification comprises the disruption of a bacterial gene with a selectable marker providing antibiotic resistance, such as kanamycin or tetracycline resistance.
Dependencies are inferred from the claim text.